Stockreport

IceCure Medical CEO Issues Letter to Shareholders & Reports Increase of 42% in ProSense® Sales for 2024 in North America

IceCure Medical Ltd. - Ordinary Shares  (ICCM) 
PDF Increase in sales of ProSense®, based on preliminary unaudited results, demonstrate growing adoption of ProSense® cryoablation for breast tumors.FDA decision on market a [Read more]